Nath Bio-Genes India Ltd Q3 FY2024 consolidated net profit rises to Rs. 3.81 crores

Nath Bio-Genes (India) Limited has reported Consolidated financial results for the period ended December 31, 2023.

Financial Results (Q3 FY2024) - QoQ Comparison

The company has reported total income of Rs. 31.7376 crores during the period ended December 31, 2023 as compared to Rs. 22.5677 crores during the period ended September 30, 2023.

The company has posted net profit / (loss) of Rs. 3.8195 crores for the period ended December 31, 2023 as against net profit / (loss) of Rs. 1.6032 crores for the period ended September 30, 2023.

The company has reported EPS of Rs. 2.02 for the period ended December 31, 2023 as compared to Rs. 0.85 for the period ended September 30, 2023.

Financials	Q3 FY2024	Q2 FY2024	% Change
Total Income	₹ 31.7376 crs	₹22.5677 crs	40.63%
Net Profit	₹3.8195 crs	₹1.6032 crs	138.24%
EPS	₹2.02	₹0.85	137.65%

Financial Results (Q3 FY2024) - YoY Comparison

The company has reported total income of Rs. 31.7376 crores during the period ended December 31, 2023 as compared to Rs.25.2974 crores during the period ended December 31, 2022.

The company has posted net profit / (loss) of Rs.3.8195 crores for the period ended December 31, 2023 as against net profit / (loss) of Rs.1.3488 crores for the period ended December 31, 2022.

The company has reported EPS of Rs.2.02 for the period ended December 31, 2023 as compared to Rs.0.71 for the period ended December 31, 2022.

Financials	Q3 FY2024	Q3 FY2023	% Change
Total Income	₹ 31.7376 crs	₹25.2974 crs	25.46%
Net Profit	₹3.8195 crs	₹1.3488 crs	183.18%
EPS	₹2.02	₹0.71	184.51%

Financial Results (9 Months Ended FY2024) - YoY Comparison

The company has reported total income of Rs.289.5869 crores during the 9 Months period ended December 31, 2023 as compared to Rs.256.3762 crores during the 9 Months period ended December 31, 2022.

The company has posted net profit / (loss) of Rs.38.4998 crores for the 9 Months period ended December 31, 2023 as against net profit / (loss) of Rs.33.5745 crores for the 9 Months period ended December 31, 2022.

The company has reported EPS of Rs.20.29 for the 9 Months period ended December 31, 2023 as compared to Rs.17.67 for the 9 Months period ended December 31, 2022.

Financials	9 Months Ended FY2024	9 Months Ended FY2023	% Change
Total Income	₹289.5869 crs	₹256.3762 crs	12.95%
Net Profit	₹38.4998 crs	₹33.5745 crs	14.67%
EPS	₹20.29	₹17.67	14.83%

Shares of Nath Bio-Genes (India) Limited was last trading in BSE at Rs. 206.95 as compared to the previous close of Rs. 212.00. The total number of shares traded during the day was 7124 in over 539 trades.

The stock hit an intraday high of Rs. 213.00 and intraday low of 206.00. The net turnover during the day was Rs. 1482877.00.

Source : Equity Bulls

Keywords

NathBioGenesIndia Q3FY24 9MFY24 ResultUpdate